GSK (NYSE:GSK) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

GSK (NYSE:GSK) issued its quarterly earnings results on Wednesday. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15, Zacks reports. GSK had a net margin of 7.97% and a return on equity of 50.62%. GSK updated its FY 2025 guidance to 2.090-2.130 EPS.

GSK Price Performance

NYSE GSK traded down $0.23 during trading hours on Friday, reaching $36.16. The company’s stock had a trading volume of 2,711,235 shares, compared to its average volume of 4,563,048. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company’s 50-day moving average is $34.21 and its two-hundred day moving average is $37.60. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The stock has a market cap of $74.93 billion, a PE ratio of 23.48, a PEG ratio of 1.38 and a beta of 0.64.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.35%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is presently 96.10%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.